Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma
Background Intracranial solitary fibrous tumor/hemangiopericytoma (SFT/HPC) often shows extracranial metastasis, and treatment options are very limited. Immune-checkpoint molecules have not been studied well in SFT/HPCs, and their role in intracranial SFT/HPCs remains unclear. Methods We investigate...
Gespeichert in:
| Veröffentlicht in: | Journal of neuro-oncology 2018-09, Vol.139 (2), p.251-259 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 259 |
|---|---|
| container_issue | 2 |
| container_start_page | 251 |
| container_title | Journal of neuro-oncology |
| container_volume | 139 |
| creator | Kamamoto, Dai Ohara, Kentaro Kitamura, Yohei Yoshida, Kazunari Kawakami, Yutaka Sasaki, Hikaru |
| description | Background
Intracranial solitary fibrous tumor/hemangiopericytoma (SFT/HPC) often shows extracranial metastasis, and treatment options are very limited. Immune-checkpoint molecules have not been studied well in SFT/HPCs, and their role in intracranial SFT/HPCs remains unclear.
Methods
We investigated the expression of programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), and tumor-infiltrating lymphocytes (TIL) in 16 patients of intracranial SFT/HPC by immunohistochemistry to determine if correlation with prognosis exists.
Results
Median overall survival (OS) of 16 patients was 9.2 years, and median follow-up of alive patients was 9.9 years. Recurrence was observed in 13 (81.3%) patients, and extracranial metastasis were observed in 6 (37.5%). PD-L1 expression was observed in all 16 tumors, whereas PD-1 expression was observed in 2. CD3 and CD8 expressions were observed in TILs in 12 and 13 patients respectively. Although the ratio of PD-L1 positive-tumor cells was not associated with OS, progression-free survival, or metastasis-free survival (MFS), diffuse staining of PD-L1 showed a trend toward shorter time to treatment failure (TTF: time to either extracranial metastasis or death) (p = 0.072). Similarly, the intense staining of PD-L1 was associated with shorter MFS (p = 0.0084) and TTF (p = 0.033). CD3 or CD8 expression was not associated with any of the prognostic parameters. In the combined analysis of PD-L1 and CD8, diffuse PD-L1 staining coupled with no or sparse CD8 expression was significantly associated with a shorter TTF (p = 0.005) and showed a trend toward shorter MFS (p = 0.0611).
Conclusions
PD-L1 is frequently expressed in intracranial SFT/HPCs, and diffuse or intense PD-L1 expression might be associated with the early occurrence of extracranial metastases. |
| doi_str_mv | 10.1007/s11060-018-2876-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2028966888</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2027405470</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-15947531c4afcaf286435ab5d2c56f5ed5c26d1036de27546d61b118161e237c3</originalsourceid><addsrcrecordid>eNp1kcuKFTEQhoMoznH0AdxIwI2bdlK5n-UweIMBNwrumnS6-kyG7uSYpNF5Dl_YNGe8IAgFIamvLn9-Qp4Dew2MmYsCwDTrGNiOW6M784DsQBnRGWHEQ7JjoE2n9vLLGXlSyi1jTBoBj8kZ32ujzF7uyI_LUpIProYU6YD1G2Kkx5wO2S0LjtTjPNMRXb2hczi4OHZA8fsxYylbRXto15qdzy4GN9MFqystQqEhtvgrVdIcqst3dApDTmuhdV1SvrjBxcVDSEfMwd_VtLin5NHk5oLP7s9z8vntm09X77vrj-8-XF1ed14KWztoyowS4KWbvJu41VIoN6iRe6UnhaPyXI_AhB6RGyX1qGEAsKABuTBenJNXp75N79cVS-2XUDbBLmLbr-eM273W1tqGvvwHvU1rjm27jTKSKWlYo-BE-ZxKyTj1xxyWJrkH1m-O9SfH-uZYvznWm1bz4r7zOrQP_13xy6IG8BNQWioeMP8Z_f-uPwG476RJ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2027405470</pqid></control><display><type>article</type><title>Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Kamamoto, Dai ; Ohara, Kentaro ; Kitamura, Yohei ; Yoshida, Kazunari ; Kawakami, Yutaka ; Sasaki, Hikaru</creator><creatorcontrib>Kamamoto, Dai ; Ohara, Kentaro ; Kitamura, Yohei ; Yoshida, Kazunari ; Kawakami, Yutaka ; Sasaki, Hikaru</creatorcontrib><description>Background
Intracranial solitary fibrous tumor/hemangiopericytoma (SFT/HPC) often shows extracranial metastasis, and treatment options are very limited. Immune-checkpoint molecules have not been studied well in SFT/HPCs, and their role in intracranial SFT/HPCs remains unclear.
Methods
We investigated the expression of programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), and tumor-infiltrating lymphocytes (TIL) in 16 patients of intracranial SFT/HPC by immunohistochemistry to determine if correlation with prognosis exists.
Results
Median overall survival (OS) of 16 patients was 9.2 years, and median follow-up of alive patients was 9.9 years. Recurrence was observed in 13 (81.3%) patients, and extracranial metastasis were observed in 6 (37.5%). PD-L1 expression was observed in all 16 tumors, whereas PD-1 expression was observed in 2. CD3 and CD8 expressions were observed in TILs in 12 and 13 patients respectively. Although the ratio of PD-L1 positive-tumor cells was not associated with OS, progression-free survival, or metastasis-free survival (MFS), diffuse staining of PD-L1 showed a trend toward shorter time to treatment failure (TTF: time to either extracranial metastasis or death) (p = 0.072). Similarly, the intense staining of PD-L1 was associated with shorter MFS (p = 0.0084) and TTF (p = 0.033). CD3 or CD8 expression was not associated with any of the prognostic parameters. In the combined analysis of PD-L1 and CD8, diffuse PD-L1 staining coupled with no or sparse CD8 expression was significantly associated with a shorter TTF (p = 0.005) and showed a trend toward shorter MFS (p = 0.0611).
Conclusions
PD-L1 is frequently expressed in intracranial SFT/HPCs, and diffuse or intense PD-L1 expression might be associated with the early occurrence of extracranial metastases.</description><identifier>ISSN: 0167-594X</identifier><identifier>EISSN: 1573-7373</identifier><identifier>DOI: 10.1007/s11060-018-2876-7</identifier><identifier>PMID: 29675794</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Adolescent ; Adult ; Apoptosis ; B7-H1 Antigen - metabolism ; Biomarkers, Tumor - metabolism ; Brain Neoplasms - metabolism ; Brain Neoplasms - mortality ; Brain Neoplasms - pathology ; Brain Neoplasms - therapy ; CD3 antigen ; CD8 antigen ; Cell death ; Female ; Follow-Up Studies ; Gene Expression Regulation, Neoplastic ; Hemangiopericytoma - metabolism ; Hemangiopericytoma - mortality ; Hemangiopericytoma - pathology ; Hemangiopericytoma - therapy ; Humans ; Immune checkpoint ; Immunohistochemistry ; Laboratory Investigation ; Ligands ; Lymphocytes ; Lymphocytes, Tumor-Infiltrating - metabolism ; Lymphocytes, Tumor-Infiltrating - pathology ; Male ; Medical prognosis ; Medicine ; Medicine & Public Health ; Metastases ; Metastasis ; Middle Aged ; Neoplasm Metastasis - diagnosis ; Neurology ; Oncology ; Patients ; PD-1 protein ; PD-L1 protein ; Prognosis ; Programmed Cell Death 1 Receptor - metabolism ; Solitary Fibrous Tumors - metabolism ; Solitary Fibrous Tumors - mortality ; Solitary Fibrous Tumors - pathology ; Solitary Fibrous Tumors - therapy ; Survival Analysis ; Treatment Failure ; Tumor cells ; Tumor-infiltrating lymphocytes ; Young Adult</subject><ispartof>Journal of neuro-oncology, 2018-09, Vol.139 (2), p.251-259</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2018</rights><rights>Journal of Neuro-Oncology is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-15947531c4afcaf286435ab5d2c56f5ed5c26d1036de27546d61b118161e237c3</citedby><cites>FETCH-LOGICAL-c438t-15947531c4afcaf286435ab5d2c56f5ed5c26d1036de27546d61b118161e237c3</cites><orcidid>0000-0001-7380-1931</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11060-018-2876-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11060-018-2876-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29675794$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kamamoto, Dai</creatorcontrib><creatorcontrib>Ohara, Kentaro</creatorcontrib><creatorcontrib>Kitamura, Yohei</creatorcontrib><creatorcontrib>Yoshida, Kazunari</creatorcontrib><creatorcontrib>Kawakami, Yutaka</creatorcontrib><creatorcontrib>Sasaki, Hikaru</creatorcontrib><title>Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma</title><title>Journal of neuro-oncology</title><addtitle>J Neurooncol</addtitle><addtitle>J Neurooncol</addtitle><description>Background
Intracranial solitary fibrous tumor/hemangiopericytoma (SFT/HPC) often shows extracranial metastasis, and treatment options are very limited. Immune-checkpoint molecules have not been studied well in SFT/HPCs, and their role in intracranial SFT/HPCs remains unclear.
Methods
We investigated the expression of programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), and tumor-infiltrating lymphocytes (TIL) in 16 patients of intracranial SFT/HPC by immunohistochemistry to determine if correlation with prognosis exists.
Results
Median overall survival (OS) of 16 patients was 9.2 years, and median follow-up of alive patients was 9.9 years. Recurrence was observed in 13 (81.3%) patients, and extracranial metastasis were observed in 6 (37.5%). PD-L1 expression was observed in all 16 tumors, whereas PD-1 expression was observed in 2. CD3 and CD8 expressions were observed in TILs in 12 and 13 patients respectively. Although the ratio of PD-L1 positive-tumor cells was not associated with OS, progression-free survival, or metastasis-free survival (MFS), diffuse staining of PD-L1 showed a trend toward shorter time to treatment failure (TTF: time to either extracranial metastasis or death) (p = 0.072). Similarly, the intense staining of PD-L1 was associated with shorter MFS (p = 0.0084) and TTF (p = 0.033). CD3 or CD8 expression was not associated with any of the prognostic parameters. In the combined analysis of PD-L1 and CD8, diffuse PD-L1 staining coupled with no or sparse CD8 expression was significantly associated with a shorter TTF (p = 0.005) and showed a trend toward shorter MFS (p = 0.0611).
Conclusions
PD-L1 is frequently expressed in intracranial SFT/HPCs, and diffuse or intense PD-L1 expression might be associated with the early occurrence of extracranial metastases.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Apoptosis</subject><subject>B7-H1 Antigen - metabolism</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Brain Neoplasms - metabolism</subject><subject>Brain Neoplasms - mortality</subject><subject>Brain Neoplasms - pathology</subject><subject>Brain Neoplasms - therapy</subject><subject>CD3 antigen</subject><subject>CD8 antigen</subject><subject>Cell death</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Hemangiopericytoma - metabolism</subject><subject>Hemangiopericytoma - mortality</subject><subject>Hemangiopericytoma - pathology</subject><subject>Hemangiopericytoma - therapy</subject><subject>Humans</subject><subject>Immune checkpoint</subject><subject>Immunohistochemistry</subject><subject>Laboratory Investigation</subject><subject>Ligands</subject><subject>Lymphocytes</subject><subject>Lymphocytes, Tumor-Infiltrating - metabolism</subject><subject>Lymphocytes, Tumor-Infiltrating - pathology</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis - diagnosis</subject><subject>Neurology</subject><subject>Oncology</subject><subject>Patients</subject><subject>PD-1 protein</subject><subject>PD-L1 protein</subject><subject>Prognosis</subject><subject>Programmed Cell Death 1 Receptor - metabolism</subject><subject>Solitary Fibrous Tumors - metabolism</subject><subject>Solitary Fibrous Tumors - mortality</subject><subject>Solitary Fibrous Tumors - pathology</subject><subject>Solitary Fibrous Tumors - therapy</subject><subject>Survival Analysis</subject><subject>Treatment Failure</subject><subject>Tumor cells</subject><subject>Tumor-infiltrating lymphocytes</subject><subject>Young Adult</subject><issn>0167-594X</issn><issn>1573-7373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kcuKFTEQhoMoznH0AdxIwI2bdlK5n-UweIMBNwrumnS6-kyG7uSYpNF5Dl_YNGe8IAgFIamvLn9-Qp4Dew2MmYsCwDTrGNiOW6M784DsQBnRGWHEQ7JjoE2n9vLLGXlSyi1jTBoBj8kZ32ujzF7uyI_LUpIProYU6YD1G2Kkx5wO2S0LjtTjPNMRXb2hczi4OHZA8fsxYylbRXto15qdzy4GN9MFqystQqEhtvgrVdIcqst3dApDTmuhdV1SvrjBxcVDSEfMwd_VtLin5NHk5oLP7s9z8vntm09X77vrj-8-XF1ed14KWztoyowS4KWbvJu41VIoN6iRe6UnhaPyXI_AhB6RGyX1qGEAsKABuTBenJNXp75N79cVS-2XUDbBLmLbr-eM273W1tqGvvwHvU1rjm27jTKSKWlYo-BE-ZxKyTj1xxyWJrkH1m-O9SfH-uZYvznWm1bz4r7zOrQP_13xy6IG8BNQWioeMP8Z_f-uPwG476RJ</recordid><startdate>20180901</startdate><enddate>20180901</enddate><creator>Kamamoto, Dai</creator><creator>Ohara, Kentaro</creator><creator>Kitamura, Yohei</creator><creator>Yoshida, Kazunari</creator><creator>Kawakami, Yutaka</creator><creator>Sasaki, Hikaru</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7380-1931</orcidid></search><sort><creationdate>20180901</creationdate><title>Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma</title><author>Kamamoto, Dai ; Ohara, Kentaro ; Kitamura, Yohei ; Yoshida, Kazunari ; Kawakami, Yutaka ; Sasaki, Hikaru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-15947531c4afcaf286435ab5d2c56f5ed5c26d1036de27546d61b118161e237c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Apoptosis</topic><topic>B7-H1 Antigen - metabolism</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Brain Neoplasms - metabolism</topic><topic>Brain Neoplasms - mortality</topic><topic>Brain Neoplasms - pathology</topic><topic>Brain Neoplasms - therapy</topic><topic>CD3 antigen</topic><topic>CD8 antigen</topic><topic>Cell death</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Hemangiopericytoma - metabolism</topic><topic>Hemangiopericytoma - mortality</topic><topic>Hemangiopericytoma - pathology</topic><topic>Hemangiopericytoma - therapy</topic><topic>Humans</topic><topic>Immune checkpoint</topic><topic>Immunohistochemistry</topic><topic>Laboratory Investigation</topic><topic>Ligands</topic><topic>Lymphocytes</topic><topic>Lymphocytes, Tumor-Infiltrating - metabolism</topic><topic>Lymphocytes, Tumor-Infiltrating - pathology</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis - diagnosis</topic><topic>Neurology</topic><topic>Oncology</topic><topic>Patients</topic><topic>PD-1 protein</topic><topic>PD-L1 protein</topic><topic>Prognosis</topic><topic>Programmed Cell Death 1 Receptor - metabolism</topic><topic>Solitary Fibrous Tumors - metabolism</topic><topic>Solitary Fibrous Tumors - mortality</topic><topic>Solitary Fibrous Tumors - pathology</topic><topic>Solitary Fibrous Tumors - therapy</topic><topic>Survival Analysis</topic><topic>Treatment Failure</topic><topic>Tumor cells</topic><topic>Tumor-infiltrating lymphocytes</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kamamoto, Dai</creatorcontrib><creatorcontrib>Ohara, Kentaro</creatorcontrib><creatorcontrib>Kitamura, Yohei</creatorcontrib><creatorcontrib>Yoshida, Kazunari</creatorcontrib><creatorcontrib>Kawakami, Yutaka</creatorcontrib><creatorcontrib>Sasaki, Hikaru</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neuro-oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kamamoto, Dai</au><au>Ohara, Kentaro</au><au>Kitamura, Yohei</au><au>Yoshida, Kazunari</au><au>Kawakami, Yutaka</au><au>Sasaki, Hikaru</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma</atitle><jtitle>Journal of neuro-oncology</jtitle><stitle>J Neurooncol</stitle><addtitle>J Neurooncol</addtitle><date>2018-09-01</date><risdate>2018</risdate><volume>139</volume><issue>2</issue><spage>251</spage><epage>259</epage><pages>251-259</pages><issn>0167-594X</issn><eissn>1573-7373</eissn><abstract>Background
Intracranial solitary fibrous tumor/hemangiopericytoma (SFT/HPC) often shows extracranial metastasis, and treatment options are very limited. Immune-checkpoint molecules have not been studied well in SFT/HPCs, and their role in intracranial SFT/HPCs remains unclear.
Methods
We investigated the expression of programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), and tumor-infiltrating lymphocytes (TIL) in 16 patients of intracranial SFT/HPC by immunohistochemistry to determine if correlation with prognosis exists.
Results
Median overall survival (OS) of 16 patients was 9.2 years, and median follow-up of alive patients was 9.9 years. Recurrence was observed in 13 (81.3%) patients, and extracranial metastasis were observed in 6 (37.5%). PD-L1 expression was observed in all 16 tumors, whereas PD-1 expression was observed in 2. CD3 and CD8 expressions were observed in TILs in 12 and 13 patients respectively. Although the ratio of PD-L1 positive-tumor cells was not associated with OS, progression-free survival, or metastasis-free survival (MFS), diffuse staining of PD-L1 showed a trend toward shorter time to treatment failure (TTF: time to either extracranial metastasis or death) (p = 0.072). Similarly, the intense staining of PD-L1 was associated with shorter MFS (p = 0.0084) and TTF (p = 0.033). CD3 or CD8 expression was not associated with any of the prognostic parameters. In the combined analysis of PD-L1 and CD8, diffuse PD-L1 staining coupled with no or sparse CD8 expression was significantly associated with a shorter TTF (p = 0.005) and showed a trend toward shorter MFS (p = 0.0611).
Conclusions
PD-L1 is frequently expressed in intracranial SFT/HPCs, and diffuse or intense PD-L1 expression might be associated with the early occurrence of extracranial metastases.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>29675794</pmid><doi>10.1007/s11060-018-2876-7</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-7380-1931</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-594X |
| ispartof | Journal of neuro-oncology, 2018-09, Vol.139 (2), p.251-259 |
| issn | 0167-594X 1573-7373 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2028966888 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adolescent Adult Apoptosis B7-H1 Antigen - metabolism Biomarkers, Tumor - metabolism Brain Neoplasms - metabolism Brain Neoplasms - mortality Brain Neoplasms - pathology Brain Neoplasms - therapy CD3 antigen CD8 antigen Cell death Female Follow-Up Studies Gene Expression Regulation, Neoplastic Hemangiopericytoma - metabolism Hemangiopericytoma - mortality Hemangiopericytoma - pathology Hemangiopericytoma - therapy Humans Immune checkpoint Immunohistochemistry Laboratory Investigation Ligands Lymphocytes Lymphocytes, Tumor-Infiltrating - metabolism Lymphocytes, Tumor-Infiltrating - pathology Male Medical prognosis Medicine Medicine & Public Health Metastases Metastasis Middle Aged Neoplasm Metastasis - diagnosis Neurology Oncology Patients PD-1 protein PD-L1 protein Prognosis Programmed Cell Death 1 Receptor - metabolism Solitary Fibrous Tumors - metabolism Solitary Fibrous Tumors - mortality Solitary Fibrous Tumors - pathology Solitary Fibrous Tumors - therapy Survival Analysis Treatment Failure Tumor cells Tumor-infiltrating lymphocytes Young Adult |
| title | Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T06%3A42%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20between%20programmed%20cell%20death%20ligand-1%20expression%20and%20extracranial%20metastasis%20in%20intracranial%20solitary%20fibrous%20tumor/hemangiopericytoma&rft.jtitle=Journal%20of%20neuro-oncology&rft.au=Kamamoto,%20Dai&rft.date=2018-09-01&rft.volume=139&rft.issue=2&rft.spage=251&rft.epage=259&rft.pages=251-259&rft.issn=0167-594X&rft.eissn=1573-7373&rft_id=info:doi/10.1007/s11060-018-2876-7&rft_dat=%3Cproquest_cross%3E2027405470%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2027405470&rft_id=info:pmid/29675794&rfr_iscdi=true |